PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application.

IF 4.4 Q1 PATHOLOGY

PATHOLOGICA Pub Date : 2022-10-01 DOI:10.32074/1591-951X-803

Luca Mastracci, Federica Grillo, Paola Parente, Irene Gullo, Michela Campora, Valentina Angerilli, Chiara Rossi, Maria Luisa Sacramento, Gianmaria Pennelli, Alessandro Vanoli, Matteo Fassan

{"title":"PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application.","authors":"Luca Mastracci, Federica Grillo, Paola Parente, Irene Gullo, Michela Campora, Valentina Angerilli, Chiara Rossi, Maria Luisa Sacramento, Gianmaria Pennelli, Alessandro Vanoli, Matteo Fassan","doi":"10.32074/1591-951X-803","DOIUrl":null,"url":null,"abstract":"Immune-checkpoint inhibitors targeting the PD-1/PD-L1 axis have brought significant clinical benefit in many solid cancer types, including gastrointestinal malignancies. However, it has been estimated that only 20-40% of patients respond to treatment. The pattern of expression and potential predictive value of PD-L1 as an immunohistochemical biomarker has been extensively studied in gastrointestinal neoplasms. Until now, its predictive value has been demonstrated, and is currently in use only in upper gastrointestinal malignancies (gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma).In this Review, we describe the technical aspects and challenges related to PD-L1 immunohistochemical assays, the current role of PD-L1 as a biomarker in clinical practice and we outline the main studies and clinical trials analyzing the prognostic and predictive value of PD-L1 in gastrointestinal cancers.","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f2/c8/pathol-2022-05-352.PMC9614301.pdf","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PATHOLOGICA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32074/1591-951X-803","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 6

Abstract

Immune-checkpoint inhibitors targeting the PD-1/PD-L1 axis have brought significant clinical benefit in many solid cancer types, including gastrointestinal malignancies. However, it has been estimated that only 20-40% of patients respond to treatment. The pattern of expression and potential predictive value of PD-L1 as an immunohistochemical biomarker has been extensively studied in gastrointestinal neoplasms. Until now, its predictive value has been demonstrated, and is currently in use only in upper gastrointestinal malignancies (gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma).

In this Review, we describe the technical aspects and challenges related to PD-L1 immunohistochemical assays, the current role of PD-L1 as a biomarker in clinical practice and we outline the main studies and clinical trials analyzing the prognostic and predictive value of PD-L1 in gastrointestinal cancers.

Abstract Image

查看原文本刊更多论文

胃肠道PD-L1评价:从生物学原理到临床应用

靶向PD-1/PD-L1轴的免疫检查点抑制剂在包括胃肠道恶性肿瘤在内的许多实体癌症类型中带来了显著的临床益处。然而，据估计，只有20-40%的患者对治疗有反应。PD-L1作为一种免疫组织化学生物标志物的表达模式和潜在的预测价值在胃肠道肿瘤中得到了广泛的研究。到目前为止，其预测价值已被证实，目前仅用于上消化道恶性肿瘤(胃食管腺癌和食管鳞状细胞癌)。在这篇综述中，我们描述了与PD-L1免疫组织化学分析相关的技术方面和挑战，PD-L1作为生物标志物在临床实践中的作用，我们概述了分析PD-L1在胃肠道癌症中的预后和预测价值的主要研究和临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PATHOLOGICA PATHOLOGY-

CiteScore

5.90

自引率

5.70%

发文量

108